and underwent optical coherence tomography directly after implantation and after 1 year.
results are not contradictory, as malapposition is an important contributor to endothelial uncoverage. 5 Acute malapposition is caused by different factors 6 like (a) marked mismatch between stent size selection and luminal diameter or (b) stent underexpansion due to inadequate pressure of implantation and/ or plaque/lesion-related factors (huge plaque formations, heavy calcifications, and aneurysmatic dilatations), and/or stiff stent platforms. 7 In addition, (c) the presence of a thrombus, that prevents apposition of stent-struts to the endothelium but resolves in the following weeks, prevents apposition of the stent to the actual vessel wall. Depending on the size of malapposition struts are being integrated into the vessel wall and covered by endothelium 1 year after stent implantation. However, large acute malappositions often present as late persistent malappositions. In contrast, late acquired stent-malappositions (LASM) result from an allergic reaction and inflammation process, which induce positive arterial remodeling with parts of the stent loosing contact to the vessel wall and, thereby, prevents endothelial coverage. 8 The known pharmacokinetic elution profile of DES and the presence of polymer fragments surrounded by giant cells and eosinophils suggests, that a reaction to the polymer causes this inflammation process. 9 Intravascular imaging can visualize the results of this process during follow-up.
Different types of polymer have been designed including PPs with
improved biocompatibility and biodegradable polymers (BP), to reduce allergic reaction, inflammation and consecutive LASM which may result in endothelial uncoverage of stent struts. Until today three studies using OCT have evaluated, if BP improves endothelial coverage during follow-up. [10] [11] [12] One study found a more complete strut coverage of Biolimus-eluting stents with BP compared to firstgeneration Sirolimus-eluting stents (SES) with permanent polymer (PP), 10 two other studies surprisingly reported even less 11 or, in trend, less 12 complete coverage of the same BES compared to second generation Everolimus-eluting stents (EES) with PP. As different characteristics of DES may contribute to the extent of late stent malapposition and endothelial uncoverage like polymer biocompatibility and the stiffness of a stent platform, 7 studies for the evaluation of potential benefits of BP have to use either similar stent-platforms or endpoints which are largely independent of the stent-platform (eg, LASM). Recent studies disregarded these principles. The aim of this study is to compare the incidence of LASM between second generation PP-DES and BP-DES using OCT after one year. for inclusion into the study, if (I) they were 18 years or older, (II) underwent elective percutaneous coronary intervention (PCI), (III) received a DES for a de novo lesion without side branch take off in a native coronary artery, and (IV) were willing to undergo follow-up coronary angiography with OCT. Patients who (I) underwent PCI due to acute coronary syndrome, (II) had a serum-creatinine >2 mg/dL, (III)
had an intolerance to contrast agent, or (IV) received a DES for an insent restenosis or into a bypass-graft were excluded from participation. Potential candidates were selected and asked to give informed consent at least 1 day before angiography. All patients included provided an informed written consent before inclusion. Patients were assigned to one of the groups using a computer-randomization system based on a precalculated randomization list. To ensure allocation concealment randomization was only performed after providing patient's initials and date of birth. The initial procedure and the OCT at baseline and after one year were performed by an experienced interventionist. Baseline OCT was used post-procedurally for documentation of procedural success only but not for guidance of PCI. In all patients dual antiplatelet therapy was prescribed for 12 months. The study is in line with the 1975 Declaration of Helsinki and was approved by the ethics committee of the Medical University of Vienna.
| Angiographic and OCT analyses
Quantitative coronary analyses (QCA) were performed using the Before OCT imaging patients were pretreated with at least 5000U intravenous bolus of unfractionated heparin and 200 µg intracoronary nitro-glycerine. Image acquisition was performed using a C7/OPTIS OCT console (Lightlab/Abbott Vascular Inc.) as recently described. 13 All OCT images were stored and analyzed using the according OCT Malapposition was defined as separation of at least one stent strut from the vessel wall. 6 OCT can show only the endoluminal surface of the strut, due to limited penetration through the metal with dorsal shadowing behind the stent strut. For exact localization of the surface of the metallic platform, the blooming effect of the endoluminal surface has to be taken into account, which extends over a distance of about 37μm between inner and outer strut reflection boundaries. 16 The actual luminal surface of the metallic platform is expected to be found in the middle of the blooming.
Accordingly, we considered a strut to be malapposed, if the distance from its endoluminal leading edge to the vessel wall was higher than the sum of the metallic strut and the abluminal polymer thickness and half of the blooming artefact (18 µm). 11, 16 This resulted in malapposition thresholds of 115 (97 + 18) µm for ZES, 107 (89 + 18) µm for EES, and 148
(130 + 18) µm for BES at baseline. Due to its BP, which completely resolves after 6-9 month, only the dimension of the metallic platform itself and half of the blooming artefact-138 (120 + 18) µm-was used for BES after 1 year. 17 In a next step, the in-stent and reference lumen areas were evaluated in stents with and without LASM. Therefore, the proximal and distal reference lumen areas were determined by choosing a proper reference frame one to two millimeters outside the stent (4-8 frames) at baseline and at one-year follow-up, respectively. In addition, the in-stent lumen area in the middle of each stent was measured. In stents with LASM after 1 year, the cross-sectional area of the LASM was evaluated in all relevant frames and the frame with the maximum LASM area was selected. In this frame also the in-stent lumen area with maximum LASM was determined. For comparison, the in-stent lumen area at the correlating position in the baseline OCT analysis was additionally determined.
| Sample size and statistical analysis
At time of the planning phase only few data existed on the incidence of LASM in second generation PP-DES and these data were assessed using intravascular ultrasound. 18 No data were available for BP-DES.
Compared to IVUS, OCT is known to have a much higher detection rate due to its 10fold higher resolution. 19 Accordingly, we performed a pilot were included into the analysis; two of these 12 patients were treated with BP-DES, 10 patients with PP-DES. All patients except one (99%)
were followed for the full study period including ambulatory visits at 4, 8, and 12 month. During the 1-year follow-up no major adverse cardiac events including myocardial infarction, stent thrombosis, or target vessel revascularization was observed. (Table 1 ).
| Angiographic follow-up

| Lesion of interest-Angiographic characteristics and OCT analyses
The angiographic characteristics at baseline (Table 2 ) and the OCT characteristics at baseline and follow up (Table 3) were also mostly similar between the groups. However, due to the narrower strut-network of the ZES, the number of struts was, in trend, higher in the PP-DES group compared to the BP-DES group. After implantation acute stent malappositions (ASM) were documented in 30 stents (51%) distributed to 22 stents treated with PP-DES (56%) and 8 with BES (40%; n.s.). After 1 year, late stent malappositions (LSM) were detected in 14 stents (24%); ASM persisted (APSM) in 9 stents after one year (7 PP-DES-18%, 2 BES-10%), whereas ASM resolved in 21 stents. In addition, LASM was documented in nine stents including five stents without and four stents with additional APSM. Per definition, these four LASM were located in stent areas with complete apposition after implantation and were spatially separated from the areas with APSM.
All LASM were located in PP-DES (n = 9; 23%), none in BP-DES (P = 0.022; Figure 2) . Two of the nine LASM were documented in each of the two lesions of the same patient, the other seven lesions were observed in different patients. All details of the late-acquired stent malappositions are shown in Table 4 . OCT example images for the different types of malapposition are presented in Figures 3 and 4 gives OCT example images how the LASM area was measured. Compared to the reference lumen area, in-stent lumen area of stents without LASM was smaller due to neointimal hyperplasia (6.7 mm 2 at baseline vs 6.1 mm 2 at 1 year; P = 0.021), whereas in-stent lumen area at maximum LASM of stents with LASM was larger due to positive remodeling (7.9 vs 10.1 mm 2 ; P = 0.002). In the 12 months follow-up angiography and OCT no evidence of intracoronary thrombus was observed.
| DISCUSSION
This is the first randomized controlled trial to compare the incidence of LASM after implantation of DES with second-generation PP and BP coatings. Our analysis indicates similar rates of ASM and APSM, but different (lower) rates of LASM using BP-DES.
| Assessment of malapposition
For the evaluation of malapposition, we measured the endoluminal strut-surface to lumen distance, which included half of the thickness of the stent strut blooming effect (18µm), in addition to the sum of the metallic strut and the abluminal polymer thickness. 11, 16 In contrast to OCT, the diagnosis of malapposition by IVUS is determined by the presence of blood speckle between the stent struts and the vessel wall.
Especially in mild cases with only a small space between abluminal strut surface and vessel wall, sensitivity may be slightly reduced due to two reasons: the area of malapposition may be concealed because of reverberations caused by the highly echo-reflective metal struts. In addition, a certain amount of thrombotic tissue may fill the space of the incomplete apposition, and thereby, may prevent detection of this space. Due to its 10-fold higher resolution and reduced reverberation around metal struts, OCT can detect an up to six-fold higher incidence of strut malappositions when compared with IVUS results. 19 
| Other factors influencing the incidence of LASM
Not only the imaging technology, but also the type of lesion may influence the incidence of LASM. The presence of a thrombus, especially in patients with acute STEMI, was demonstrated to predict LASM. 20 A thrombus can prevent apposition of stent struts to the endothelium, and may leave a space after resolution. In our study, culprit lesions in STEMI patients were excluded. IVUS analyses on LASM after stenting of patients with STEMI showed a high rate of 25-30% after DES implantation. 21 It is also conceivable that the strut-density could have an influence on the threshold to trigger an allergic reaction. So far, strut-density has clinical outcome. On average the length of implanted DES in both study groups was similar (18.7 mm in both groups), however, the strut-count per stent was significantly lower in the Xience stent (n = 197.7) compared to the Resolute stent (n = 238.6). 22 An even lower density of stent-struts was documented for the biomatrix stent in the ORION study compared to the Xience stent. 23 Our analysis confirms these results as we also found a lower strut-density of the BP-DES compared to the PP-DES. As higher doses of a certain allergen are more likely to induce an allergy, 24 also the strut-density and the associated density of polymer may influence the incidence of a LASM. Up to now, no study tested this hypothesis.
| Rate of LASM
Up to now OCT data on the incidence of LASM in second generation PP-DES are still rare. Recently, an OCT study investigating predominantly second generation DES reported a LASM rate of 15% after 6 months.
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This rate is in good correlation to the rate of 23% in our study after a twice as long observation period of 1 year, as the rates of LASM rise with increasing observation time. 25 As the BES with BP behaves like a bare metal stent after 6-9 months, a much lower LASM rate could be expected:
the observed LASM rate of 0% for BP-DES in our study has been described in various studies 26, 27 and only few studies demonstrated low rates of LASM in context with these stents. Direct stent implantation in patients with STEMI (as discussed before) and atherectomy before stenting were determined as independent predictors for the development of LASM in bare metal stents. 28 Atherectomy causes deep arterial aggression that may facilitate positive remodeling. In our study, atherectomy before stenting was not used and patients with STEMI were excluded from participation.
Rare data are available comparing first versus second generation DES.
However, two IVUS-studies suggest a trend toward a lower incidence in second generation DES. 18, 29 Recently, an observational OCT based analysis of 351 patients could not detect a difference between first or second generation DES and DES with BP after a mean observational period of less than 6 months. 20 However, this time period is too short to demonstrate the beneficial effect of a BP, as the degradation time of this degradable polymer is 6-9 months. 30 In our study the OCT follow up was performed 12 months after stent implantation. This time period can be assumed to be necessary to demonstrate the potentially positive influence of BP on prevention of LASM.
| Limitations
In our study neither the interventionist nor the patient was blinded to the implanted stent type. However, the study endpoint was not a clinical but a surrogate endpoint, which could neither be influenced by the interventionist nor by the patient. Importantly, the analysts of the OCT studies were blinded.
| CONCLUSION
LASM is the major risk factor for late stent thrombosis. 3, 4 Our results suggest lower rates of late and very late stent thrombosis in favor of BP-DES compared to second generation PP-DES. As the development of LASM itself takes several months, the potential advantage of BP to reduce the rate of late stent thrombosis will get apparent at the earliest after one year.
Indeed, a recent meta analysis demonstrated fewer rates of late stent thrombosis (>12 months) with BP-DES compared to PP-DES. 31 However, these analyses included mainly first generation DES. As second generation DES were demonstrated to cause fewer rates of late stent thrombosis compared to first generation DES, 1 long-term observations are needed to evaluate differences between BP-DES and second generation PP-DES. Up to now, only few studies compared second generation PP-DES to BP-DES.
Thereby, it has to be taken into account, that other stent-related factors than PP-induced LASM may influence the risk for stent-thrombosis, either directly, like the thickness of the stent-struts, 32 or indirectly, like stiffer stentplatforms which more frequently cause acute (persisting) malapposition. 7 Newer generation DES have largely overcome these problems by using thinner stent struts and less stiff metal alloys including cobalt-chromium and platinum-chromium. However, many studied BP-DES either have an oldfashioned, stiff stent-platform with relatively thick stent struts (BESBiomatrix, Biosensors and Nobori, Terumo Interventional Systems), or, at least, use stiffer metal alloys (stainless steel-Supralimus, Sahajanand Medical). 31 When comparing these stents with newer generation PP-DES, the benefits of the BP may be offset by the disadvantages of their platform.
Our study suggests, that the concept of BP to reduce LASM works but, presumably, has to be linked with a modern stent platform to show its benefit compared to newer generation PP-DES. Indeed, in a recent landmark analysis ranging from 1 day to 2 years, the new BP-DES (Platinum chromium, Synergy, Boston), in trend, reduced the rate of stent thrombosis compared to the second-generation PP-DES (Promus Element, Boston). 33 
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